In addition to the complications caused by the disease itself, multiple myeloma also has drug side effects caused by early first- and second-line high-intensity treatment programs, including gastrointestinal reactions, bone marrow suppression, liver and kidney damage, and cardiac damage. It needs high attention, treatment and follow-up. Among them, for the problem of low blood status, it has been found that many patients are still confused recently.
How much is a low blood routine index for myeloma considered serious?
Most chemotherapy drugs for multiple myeloma have varying degrees of bone marrow suppression. In the early stage of myeloma patients in the stage of bone marrow suppression, white blood cells, especially granulocytes, can be reduced in the early stage. In severe cases, platelets and hemoglobin can be reduced, which is the performance of pancytopenia.
Generally, myeloma patients will have bone marrow suppression for about 7-14 days after chemotherapy. They mainly observe the blood routine and pay attention to several major blood cells, one is hemoglobin, the other is white blood cells, the third is granulocytes, and the fourth is platelets, depending on the level of risk ( Fourth degree is the most severe) .
Hemoglobin is 109-95 for one degree, 94-80 for second degree, 79-65 for third degree, and <65 for fourth degree;
White blood cells are 3.9-3.0 for first degree, 2.9-2.0 for second degree, 1.9-1.0 for third degree, and <1.0 for fourth degree;
Granulocytes are 1.9-1.5 for the first degree, 1.4-1.0 for the second degree, 0.9-0.5 for the third degree, and <0.5 for the fourth degree;
Platelets are 99-75 for one degree, 74-50 for second degree, 49-25 for third degree, and <25 for fourth degree;
In the stage of myelosuppression, myeloma patients may feel fatigued and weak, and their resistance is decreased. During this period, any virus, fungi, etc. can easily find the “head” of the myeloma patient, and infection, fever, etc. will occur. In addition, spontaneous Manifestations of sexual bleeding.
To sum up, emphasize the attention and prevention of blood in the process of treatment! If the suppression is severe, the treatment of the myeloma itself will stagnate or even worsen the disease. Regarding the treatment situation in this regard, effective combination programs can be combined to alleviate the toxic and side effects caused by chemotherapy in myeloma patients, so that the blood picture and main drug intervention can be supported.